Liothyronine Sodium Drug Asset Due Diligence Report 2026

This Liothyronine Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Liothyronine Sodium can convert its Small molecule drug profile and THR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Liothyronine Sodium (query alias: liothyronine)
Modality / target	Small molecule drug; THR; THR agonists
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	King Pharmaceuticals Research & Development LLC, Takeda Pharmaceutical Co., Ltd.

The MCP disease footprint includes Goiter, Thyroiditis, Chronic, Anaphylaxis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07424183	Phase 2	Not yet recruiting	60	ThyPRO Composite QOL Scale
NCT07346157	Phase 1/2	Not yet recruiting	69	Proportion of participants experienced an Adverse Event
NCT07568574	Not Applicable	Enrolling by invitation	60	The incidence and severity of Treatment-related adverse events (TRAEs), including adverse events (AEs) and serious adverse events (SAEs), as assessed by the study physicians from baseline to 5.5 years after enrollment.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism

Phase 3; n=12; evaluation: Positive. Reported fields: LDL-C = 32.0 mg/dl ; LDL-C = -19.0 mg/dl

Developing Oral LT3 Therapy For Heart Failure With Preserved Ejection Fraction

Phase 1/2; n=28; evaluation: not stated. Reported fields: Number of Participants With Atrial Fibrillation or Ventricular Tachycardia >=4 Beats = 12 Number of participants with events ; Number of Participants With Atrial Fibrillation or Ventricular Tachycardia >=4 Beats = 10 Number of participants with events ; -

Developing Oral LT3 Therapy For Heart Failure With Reduced Ejection Fraction

Phase 1/2; n=28; evaluation: not stated. Reported fields: Cardiac Rhythm Monitoring by 14 Day Patch Rhythm Assessment = 19 Number of participants with events ; Cardiac Rhythm Monitoring by 14 Day Patch Rhythm Assessment = 11 Number of participants with events ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Liothyronine Sodium addresses Goiter, Thyroiditis, Chronic, Anaphylaxis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 14 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: THR records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-01-13	Sino Biopharmaceutical Ltd. acquires Hygieia Pharmaceuticals Co., Ltd.	Phase 1	US$172.1M stated total
2025-12-17	Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program	Approved	Financial terms not disclosed
2025-10-15	Egetis and taiba rare Sign Exclusive Distribution and Early Access Agreement to Enable Named Patient Sales of Emcitate® in the Gulf Region	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Oral solution comprising liothyronine sodium”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the same”. The milestone feed surfaced a patent-application signal described as “Sustained release compositions comprising liothyronine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO